CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Common Challenges Hampering Clinical Laboratory Services

Common Challenges Hampering Clinical...

Adherehealth and Levrx Technology Establish a Strategic Partnership to Improve Medication Optimization

Adherehealth and Levrx Technology...

Clinical Researchs Most Recent Developments

Clinical Researchs Most Recent...

Aceragen Receives Grant from Cystic Fibrosis Foundation to Advance Novel Therapy

Aceragen Receives Grant from Cystic...

Giuliano to Lead Finance-Related Leadership Functions as New CFO at Aeterna

Giuliano to Lead Finance-Related...

Top Ways Netsuite Transforms Life Science Industry for Good

Top Ways Netsuite Transforms Life...

China biopharma sector focuses on innovation.

China biopharma sector focuses on...

4 Common Challenges in Clinical Trials - How Are You Addressing Them?

4 Common Challenges in Clinical...

Common Challenges Hampering Clinical Laboratory Services

Common Challenges Hampering Clinical...

Adherehealth and Levrx Technology Establish a Strategic Partnership to Improve Medication Optimization

Adherehealth and Levrx Technology...

Clinical Researchs Most Recent Developments

Clinical Researchs Most Recent...

Aceragen Receives Grant from Cystic Fibrosis Foundation to Advance Novel Therapy

Aceragen Receives Grant from Cystic...

Giuliano to Lead Finance-Related Leadership Functions as New CFO at Aeterna

Giuliano to Lead Finance-Related...

Top Ways Netsuite Transforms Life Science Industry for Good

Top Ways Netsuite Transforms Life...

China biopharma sector focuses on innovation.

China biopharma sector focuses on...

4 Common Challenges in Clinical Trials - How Are You Addressing Them?

4 Common Challenges in Clinical...

Rain Therapeutics and Roche to Jointly Conduct Immunotherapy Trial Solid Tumor Treatment

Life Sciences Review Life Sciences Review | Monday, January 10, 2022
Tweet

Milademetan and Atezolizumab, in combination, will assess the potential for MDM2-checkpoint inhibition in genetically selected patient populations.


FREMONT, CA: Patients benefit from clinical trials because they help researchers find cures and preventative measures in the fight against diseases. It is impossible to discover what works in the laboratory or on animals and what does not in humans until clinical trials are conducted. Rain Therapeutics Inc., a late-stage company developing precision oncology therapeutics, has entered into a clinical supply agreement with Roche to supply atezolizumab, an anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody.


“We are excited to evaluate the combination of MDM2 inhibition and cancer immunotherapy with milademetan and atezolizumab, and believe it presents a strong mechanistic rationale,” states Avanish Vellanki, co-founder and chief executive officer of Rain. 


 


“We believe the therapeutic index afforded by milademetan will enable synergistic combination with PD-L1 checkpoint inhibition and are excited about the potential for favorable results from the Phase 1 study to support moving into subsequent studies across various MDM2-dependent cancers.”


Milademetan, an oral mouse double minute 2 (MDM2) inhibitor, is being evaluated in clinical trials with atezolizumab to treat patients from genetically distinct populations. Rain will sponsor the anticipated clinical trials under this agreement, while Roche will supply atezolizumab.


A Phase 1 clinical trial will be conducted to assess the safety, tolerability, and efficacy of milademetan in combination with atezolizumab in patients with advanced solid tumors who lack cyclin-dependent kinase inhibitor 2A (CDKN2A) but have wildtype p53. CDKN2A encodes the tumor suppressor p14ARF, which acts as an MDM2 inhibitor, and CDKN2A deficiency may result in MDM2-dependent cancers. The Phase 1 clinical trial will begin in the second half of 2022. Additional tumor types may be included in subsequent Phase 2 clinical trials evaluating the combination of milademetan and atezolizumab.


Weekly Brief

loading
Top 10 Clinical Trial Services Companies - 2022
Top 10 Emerging Clinical Trial Management Companies - 2022
Top 10 Clinical Trial Management System Companies - 2022
Top 10 Clinical Trial Services Companies - 2022
Top 10 Emerging Clinical Trial Management Companies - 2022
Top 10 Clinical Trial Management System Companies - 2022
> <
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue

Read Also

Role of Predictive Genomics in Sustainable Healthcare

Role of Predictive Genomics in Sustainable Healthcare

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to Regulatory Intelligence

A rise in DNA Sequencing Market is expected in coming years

A rise in DNA Sequencing Market is expected in coming years

Omniabio Inc. Announces Private Investor

Omniabio Inc. Announces Private Investor
Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Lithuania's Vision to Become a Biotech Hub in Europe

Lithuania's Vision to Become a Biotech Hub in Europe

Bridging the Diversity Gap in Genomics

Bridging the Diversity Gap in Genomics

How does Biotechnology Provide Solutions to Human Needs?

How does Biotechnology Provide Solutions to Human Needs?
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/rain-therapeutics-and-roche-to-jointly-conduct-immunotherapy-trial-solid-tumor-treatment-nwid-686.html